Mustang Bioの空売り状況は、投資家がMustang Bioの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Mustang Bio (NASDAQ:MBIO) 株価情報, 空売り情報

Mustang Bio

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio Inc

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) reported quarterly earnings of $1.86 per share which missed the analyst consensus estimate of $2.77 by 32.85 percent. This is a 44.97 percent decrease over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $787.58 million which missed the analyst consensus estimate of $810.94 million by 2.88 percent. This is a 4.35 percent increase over sales of $754.77 million the same period last year.

Earnings

Earnings Misses

News

SAIA

Saia Q1 EPS $1.86 Misses $2.77 Estimate, Sales $787.58M Miss $810.94M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) affirms FY2025 GAAP EPS guidance from $24.05-$25.85 to $24.05-$25.85 vs $24.97 analyst estimate. Affirms FY2025 sales outlook from $72.80 billion-$75.80 billion to $72.80 billion-$75.80 billion vs $74.63 billion estimate.

Guidance

HCA Healthcare Affirms FY2025 GAAP EPS Guidance of $24.05-$25.85 vs $24.97 Est; Affirms FY2025 Sales Guidance of $72.80B-$75.80B vs $74.63B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) affirms FY2025 sales outlook from $3.23 billion-$3.43 billion to $3.23 billion-$3.43 billion vs $3.34 billion estimate.

PHIN

Phinia Affirms FY2025 Sales Guidance of $3.23B-$3.43B vs $3.34B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.01 by 6.93 percent. This is a 12.96 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $796.00 million which missed the analyst consensus estimate of $814.39 million by 2.26 percent. This is a 7.76 percent decrease over sales of $863.00 million the same period last year.

Phinia Q1 Adj. EPS $0.94 Misses $1.01 Estimate, Sales $796.00M Miss $814.39M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported quarterly earnings of $6.45 per share which beat the analyst consensus estimate of $5.76 by 11.98 percent. This is a 20.34 percent increase over earnings of $5.36 per share from the same period last year. The company reported quarterly sales of $18.32 billion which beat the analyst consensus estimate of $18.26 billion by 0.35 percent. This is a 5.66 percent increase over sales of $17.34 billion the same period last year.

Earnings Beats

HCA Healthcare Q1 Adj. EPS $6.45 Beats $5.76 Estimate, Sales $18.32B Beat $18.26B Estimate

Needham analyst Scott Berg reiterates SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and maintains $210 price target.

Price Target

Reiteration

Analyst Ratings

SPSC

Needham Reiterates Buy on SPS Commerce, Maintains $210 Price Target

In a move indicating a possible easing of trade tensions, China has reportedly started to exempt some U.S. imports from high tariffs and is proactively seeking feedback from companies on other key items they want excluded from them.
What Happened: Companies in China say that they have been approached by officials to identify U.S. goods that are essential and difficult to replace, reported Reuters.
Some pharmaceutical imports and aerospace parts like engines and landing gear have reportedly already been excluded from the 125% tariffs. American Chamber of Commerce in China President Michael Hart confirmed that multiple member firms, especially in pharma, have not had to pay tariffs.
See Also: <a href="https://www.benzinga.com/25/04/45003278/flexport-ceo-joins-galloway-tariff-workarounds-and-fraud-will-force-trump-to-walk-back-on-trade-war-with-china">Trump Will Be First To &#8216;Blink&#8217; In China Trade War, Flexport&#8217;s Ryan Petersen Tells Scott Galloway: &#8216;The Market Finds A Way&#8217; Amid Tariff Workarounds, Fraud Surge</a>
Why It Matters: The exemptions are being made as both Beijing and Washington demonstrate <a href="https://www.benzinga.com/markets/25/04/44942449/trump-pledges-substantial-cut-in-china-tariffs-but-refuses-to-make-it-zero-if-they-dont-make-a-deal-we-will-set-the-deal">noticeable signs of de-escalation</a> in a trade war that has upset markets and stressed global supply chains. "As a quid-pro-quo move, it could provide a potential way to de-escalate tensions," said Alfredo Montufar-Helu of the Conference Board's China Center.
However, he said that neither side seems keen to make the first formal move to make a deal. China&#8217;s Ministry of Commerce <a href="https://www.benzinga.com/markets/25/04/44973283/china-denies-trumps-trade-talk-assertion-calls-for-abolition-of-unilateral-tariffs-no-factual-basis">denied rumors</a> of trade discussions with the U.S. on Thursday. 
While China's leadership has not made any official statement about the exemptions, the move seems to be targeted at shielding domestic industries from even more pressure. With major sectors still reliant on American inputs— ranging from ethane to specialty drugs—the exemptions may be just the beginning. "For irreplaceable goods, there's clear interest in unilateral exemptions," Montufar-Helu observed.
Read Next: <a href="https://www.benzinga.com/25/04/44999388/charlie-munger-once-slammed-the-idea-of-escalating-tariffs-in-the-us-china-trade-war-calling-it-massively-stid-heres-why-he-believed-both-sides-should-get-used-to-feeling-roughed-up-and-strike-a-deal">Charlie Munger Once Observed That A Full-Scale US-China Tariff War Was &#8216;Massively Stupid&#8217;: The Legendary Investor Didn&#8217;t Mind If Both Beijing And Washington Got Bruised Up In Talks Though — Here&#8217;s Why</a>
Image Via Shutterstock

Global

Economics

Markets

General

China Reportedly Begins Exempting Key US Imports From Tariffs, Including Pharma And Aerospace Parts

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Fartcoin&#8216;s impressive price surge has become one of the most discussed topics in the cryptocurrency world, as many are still adjusting to its unconventional branding and strong performance despite macroeconomic challenges.
What happened: The Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)-based memecoin has surged by 77.61% over the past month, making it the second-best-performing cryptocurrency during this time. It has also gained over $450 million in market capitalization, now ranking as the sixth-largest memecoin.
These gains have come at a time when trade tensions dominated headlines. Fartcoin withstood President Donald Trump&#8217;s <a href="https://www.benzinga.com/news/25/04/44893608/trumps-tariffs-add-financial-strain-for-new-parents-amid-rising-baby-gear-costs">sweeping tariff measures</a> against key partners, which sent stock and cryptocurrency heavyweights like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) plunging.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/04/44971891/sec-teams-up-with-nayib-bukele-led-el-salvador-for-a-crypto-regulatory-sandbox">SEC Zooms In On Nayib Bukele-Led El Salvador&#8217;s Crypto Regulation Model</a>
FARTCOIN topped out at $2.61 in January and then crashed by over 90% over the next two months before beginning a bullish rebound. Its year-to-date gains stood at 18%.
On the other hand, cryptocurrency derivatives of gold have netted higher returns.&nbsp;
Tether Gold and PAX Gold, both backed by physical gold, were among the safest cryptocurrency bets this year, yielding over 26%.
Their rise has followed the increasing demand for gold as a haven, as spot gold itself has risen 25.77% year-to-date.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>YTD Gains +/-</td>
<td>Price (Recorded at 6:30 a.m. ET)</td>
</tr>
<tr>
<td>Tether Gold (CRYPTO: XAUT)</td>
<td>+26.31%</td>
<td>$3,312.35</td>
</tr>
<tr>
<td>Pax Gold (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/paxg/usd">PAXG</a>)</td>
<td>+26.24%</td>
<td>$3,317.17</td>
</tr>
<tr>
<td>Fartcoin (FARTCOIN)</td>
<td>+18.05%</td>
<td>$1.10</td>
</tr>
</tbody>
</table>
</figure>
Benzinga Note: Investing in meme coins is highly speculative and involves significant risk. Meme coins often lack intrinsic value and are driven by market sentiment, social media trends, and speculative trading. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44971214/solana-staking-etf-surges-18-in-debut-week-heres-how-much-cathie-woods-ark-invest-has-parked-in-it">Solana Staking ETF Surges 18% In Debut Week—Here&#8217;s How Much Cathie Wood&#8217;s Ark Invest Has Parked In It</a></li>
</ul>
Image Via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trading Ideas

$BTC

$PAXG

$SOL

MSTR

Fartcoin Might Capture The Meme Coin Spotlight In 2025, But These Gold-Backed Cryptocurrencies Have Outpaced Its Growth In Recent Trends

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Fermium Research analyst Frank Mitsch upgraded the rating for Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Hold to Buy and maintained the price target of $35. Dow shares closed at $29.76 on Thursday. <a href="https://www.benzinga.com/quote/DOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Bradley Thomas upgraded Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) from Sector Weight to Overweight and maintained the price target of $266. Lowe&#8217;s shares closed at $222.05 on Thursday. <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst James Hardiman upgraded the rating for Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) from Neutral to Buy and announced a $72 price target. Hasbro shares closed at $60.37 on Thursday. <a href="https://www.benzinga.com/quote/HAS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Bradley Thomas upgraded the rating for Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) from Sector Weight to Overweight and maintained the price target of $181. Williams-Sonoma shares closed at $151.40 on Thursday. <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Faham Baig upgraded Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) from Sell to Neutral and raised the price target from $130 to $170. Philip Morris shares closed at $170.07 on Thursday.  <a href="https://www.benzinga.com/quote/PM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LOW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072007/image-172-1024x595.png" alt="" class="wp-image-888508" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072007/image-172-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072007/image-172-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072007/image-172-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/25072007/image-172.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wells Fargo analyst Rich Kwas initiates coverage on Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Equal-Weight rating and announces Price Target of $20.

Initiation

Wells Fargo Initiates Coverage On Sensata Technologies with Equal-Weight Rating, Announces Price Target of $20

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) with a Buy and maintains $3.9 price target.

HC Wainwright & Co. Reiterates Buy on Largo, Maintains $3.9 Price Target

The S&amp;P 500 Index tracked by SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) could plunge as low as 3,700 points even in a &#8220;mild recession&#8221; scenario, representing a potential 37% decline from its January levels, according to Wolfe Research.
What Happened: Chris Senyek, the firm&#8217;s Chief Investment Strategist, warns that the index could fall between 3,700 and 4,100 amid economic contraction, as <a href="https://www.cnbc.com/2025/04/24/sp-500-could-tumble-to-3700-in-a-mild-recession-says-wolfe-research.html">reported</a> by CNBC, reflecting heightened concerns over trade policy uncertainty.
&#8220;If uncertainty caused by tariff policy were to push the U.S. economy into recession in 2025, we&#8217;d expect SPX EPS to fall at least 15% from current levels,&#8221; Senyek wrote Thursday. This would align with the median 16.7% earnings decline observed across the past four recessions.
The strategist projects S&amp;P 500 earnings per share could drop to approximately $225 from the currently estimated $266, coinciding with about 1% negative real year-over-year Gross Domestic Product growth.
Why It Matters: The index has struggled since President Donald Trump&#8216;s April 2 tariff announcement, which triggered significant market volatility. After briefly entering bear market territory earlier this month, the S&amp;P 500 remains 11% below February&#8217;s all-time high and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">down more than 6.50% year-to-date</a>.
Senyek expects price-to-earnings ratios would compress from the current 19.4x to historical averages between 16.6x and 18.4x in a recessionary environment, contributing to the projected market decline.
U.S. markets have recently staged a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">three-day rally amid cooling trade tensions</a> and positive earnings surprises, though prominent investors like Cathie Wood have warned that tariffs represent &#8220;tax increases&#8221; that could <a href="https://www.benzinga.com/markets/25/04/45000154/cathie-wood-warns-trumps-tariffs-are-tax-increases-that-hurt-growth-but-says-innovation-will-thrive-in-the-turmoil">hamper economic growth</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44969001/65-year-old-with-110k-saved-asks-if-he-can-retire-in-7-years-dave-ramsey-says-you-have-no-money-and-tells-him-to-stop-401k-contributions" target="_blank" rel="noreferrer noopener">65-Year-Old With $110K Saved Asks If He Can Retire in 7 Years — Dave Ramsey Says ‘You Have No Money' and Tells Him to Stop 401(k) Contributions</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

S&P 500 Could Crash 37% To 3,700 If Tariff Fallout Triggers Recession, Warns Wolfe Research

Wells Fargo analyst Tiago Fauth downgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Overweight to Equal-Weight and lowers the price target from $395 to $314.

Downgrades

UTHR

Wells Fargo Downgrades United Therapeutics to Equal-Weight, Lowers Price Target to $314

Wells Fargo analyst Ken Gawrelski maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Equal-Weight and raises the price target from $167 to $175.

GOOG

GOOGL

Wells Fargo Maintains Equal-Weight on Alphabet, Raises Price Target to $175

Rosenblatt analyst Barton Crockett maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Neutral and lowers the price target from $205 to $189.

Rosenblatt Maintains Neutral on Alphabet, Lowers Price Target to $189

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/25064300/XiaoNoodlesJ-900x600-1.png" alt="" class="wp-image-11556" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/25064300/XiaoNoodlesJ-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/25064300/XiaoNoodlesJ-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/25064300/XiaoNoodlesJ-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The restaurant company wants to keep expanding its network of spicy Chongqing noodle shops, but price cuts may be eating into profits
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>The noodle chain more than doubled its revenue from 418 million yuan in 2022 to 1.15 billion yuan last year</li>
<li>But the operator's same-store sales slipped from 740 million yuan in 2023 to 709 million yuan last year</li>
</ul>
Noodle dishes from Chongqing, famous for their spicy flavors in a fiery soup, are about to go on the menu for equity investors.
A fast-growing noodle shop chain that specializes in hot signature dishes from southwest China has filed to&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107294/documents/sehk25041500046.pdf">list</a>&nbsp;its shares on the Hong Kong stock market, aiming to fund an expansion across more parts of the mainland and into overseas markets.
Guangzhou Xiao Noodles Catering Management Co. Ltd.&nbsp;started out as a local food outlet serving up bowls of noodles spiced with chili oil and Sichuan seasonings. It is now aiming to become the first chain of Chinese-style noodle shops to trade as a public company on the Hong Kong Stock Exchange.
The company bases its brand name on the Chongqing dish popularly known as "xiao mian", or little noodles. The dining chain ranked as China's biggest operator of Sichuan-Chongqing noodle restaurants by sales value last year and placed fourth in the general category of noodle shops, according to Frost &amp; Sullivan data cited in the IPO application.
The company also claimed the top spot for offline sales of Chongqing noodles, noodles with peas and meat sauce and hot and sour sweet potato noodles for three consecutive years from 2022, according to the research report.
Although it owes its success to Chongqing's tasty cuisine, the firm originated far away in Guangzhou, a southern city associated with milder flavors. Founder Song Qi was born in Heilongjiang province in northeastern China but left his hometown to study science in Guangzhou before obtaining a master's degree from the Hong Kong University of Science and Technology. Later he became a trainee manager at a Hong Kong branch of the fast food chain McDonald's.
Song once revealed in a media interview that from his very first McDonald's meal he dreamed about one day starting his own brand and even challenging the supremacy of the U.S. burger giant.
<h4 class="wp-block-heading">Food science</h4>
He opened the first Xiao Noodles restaurant in 2014 with two other graduates from Guangzhou's South China University.
A scientific mindset turned out to be an asset, helping the business to resolve a standardization challenge that had plagued chains selling Chinese-style noodles. Song studied the traditional craft of noodle making in Chongqing but was troubled by some of the approximate amounts and imprecise instructions. Instead, he set about quantifying ingredients and documenting steps in order to preserve the original taste while producing noodle dishes at scale.
Just three months after the first outlet opened, the business got an infusion of 2 million yuan ($274,132) in angel capital to fund upgraded operations. &nbsp;Meanwhile, the company set out to instill an appetite for its noodle dishes across the nation and around the clock, for breakfast, lunch or as a late-night snack, with some restaurants staying open 24 hours a day.
It built a presence in airports, railway stations, residential areas, shopping malls, college campuses and offices to cater to a range of diners.
By 2021, the company was valued at nearly 3 billion yuan after investments from&nbsp;Jiumaojiu&nbsp;(9922.HK), Best Food Holding under Lenovo's Hony Capital, Country Garden and the dumpling chain XiJiaDe.
Even with its ample resources, the company did not reach the milestone of 100 stores until its seventh year of business. The brand branched out into a franchise model in 2019, adding another 100 stores in just two years between 2021 and 2023. By April this year, the chain comprised 374 restaurants across 22 cities on the Chinese mainland and six outlets in Hong Kong.
Revenue soared on the back of the rapid growth, going from 418 million yuan in 2022 to 1.15 billion yuan last year with a compound annual growth rate of around 66%, outpacing other Chinese-style noodle businesses in the past three years. It went from posting a loss of 35.97 million yuan in 2022 to reporting a 45.91 million yuan profit a year later, rising to 60.70 million yuan in 2024.
<h4 class="wp-block-heading">Price trade-off</h4>
At the end of last year, the chain was operating 360 outlets, 80% of them in first-tier cities. Breaking that down by business model, 279 were owned by the company and 81 were franchises. The shops owned by the chain remained the main revenue driver, accounting for 86.7% of turnover in 2024.
While earnings and profits have been growing, the risk of expanding too quickly remains real, amid an uncertain outlook for the Chinese economy and fragile consumer confidence. The company's accounts were in the black for the past two years but profit per store dropped from 182,000 yuan to 169,000 yuan. Xiao Noodles earned 60.70 million yuan in profit last year on 42.09 million orders, equivalent to just 1.4 yuan per order.
Same-store sales also dropped from 740 million yuan in 2023 to 709 million yuan last year, falling 4.2% nationwide and 5.14% in first-tier cities.
Other metrics are also flashing danger signs. Average spending per order dropped from 36.1 yuan in 2022 to 32 yuan in 2024 after the company cut its prices to lure in more customers.
Rapid expansion has strained the corporate finances, with net current liabilities surging from 148 million yuan in 2022 to 242 million yuan, and just 42.19 million yuan of cash left on hand.
In response, Xiao Noodles has decided to expand its reach, venturing into lower-tier Chinese cities and targeting international markets such as Singapore, as well as scaling up its franchise network. As it prepares to face the scrutiny of Hong Kong investors, the company has changed its advertising slogan from "sharing the delight of Xiao Noodles outside Chongqing" to "sharing the delight of Chongqing noodles across the globe".
The staple bowl of steaming noodles is a cutthroat business in China, with stiff competition from the likes of Hefu Noodles, Wuyebanmian and Mr. Lee California Beef Noodle.
To succeed in its expansion strategy, Xiao Noodles will need to keep satisfying a widening base of customers with its selection of spicy dishes.

Asia

IPOs

Xiao Noodles Serves Up IPO Plan To Take Its Tangy Taste Global

IRWD

Ironwood Pharmaceuticals Raises 2025 Adj. EBITDA Guidance To Over $105M

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has announced a range of promotions for customers in the U.S. on all of its models in a bid to increase declining sales figures.
What Happened: The EV giant's promotions include FSD transfers on all new Model 3, Model Y, Model S, Model X, and the Cybertruck orders free of charge. 
&#8220;FSD (Supervised) cannot be transferred from a Foundation Series Cybertruck, Model Y Launch Series or a vehicle under an active lease. Used vehicle, business and commercial orders are not eligible,&#8221; Tesla said on its website.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here are all the promotions <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a> announced today in the US: • Free FSD transfer for new Model 3, Model Y, Model S, Model X and Cybertruck orders in North America (excluding Foundation Series &amp; Launch Series). • 0% APR financing for new Model 3 orders. Applies to new orders… <a href="https://t.co/wyv0djtVvW">pic.twitter.com/wyv0djtVvW</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1915586753077129426?ref_src=twsrc%5Etfw">April 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Other offers include 0% APR financing on new Model 3 orders. There's also a $2,000 discount on the purchase price of the new Model Y available to owners of the original Model Y.
Why It Matters: The discounts come at a time when Tesla is experiencing a decline in sales in the U.S. A recent report released by the California New Car Dealers Association (CNCDA) showcases a <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">15% decline in new registrations </a>for Tesla vehicles in the state.
The company has also experienced a 71% plunge in YoY profits in Q1 2025, and a <a href="https://www.benzinga.com/25/04/44975755/tesla-sales-decline-28-in-europe-as-ev-car-market-experiences-growth-report">28% decline in European sales</a>, even as the EV market share grew in the region.
Tesla recently released a cheaper trim of the Cybertruck, with fewer features and a more accessible price point. Interestingly, Elon Musk's company also <a href="https://www.benzinga.com/markets/25/04/44919745/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-sales">pivoted its marketing strategy </a>for the Cybertruck, in a bid to enhance its appeal among traditional pickup truck buyers.
It's worth noting that Tesla announced at the Tuesday evening earnings call that <a href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year">more affordable models </a>are on their way, and they will be based on the current Tesla line-up.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44971783/piper-sandler-puts-400-price-target-on-tesla-it-appears-our-best-case-scenario-has-materialized">Piper Sandler Puts $400 Price Target On Tesla: &#8216;It Appears Our Best-Case Scenario Has Materialized&#8217;</a></li>
</ul>
Image Via Shutterstock

Tech

TSLA

Tesla Rolls Out Free FSD Transfers On All US Models, Including Cybertruck Amid Poor Sales

GOOG: 6% &#x7C; <a href="https://www.benzinga.com//node/45003886">Alphabet shares are trading higher following better-than-expected Q1 financial results.</a>
&nbsp;
INTC: -7% &#x7C; <a href="https://www.benzinga.com//node/45003864">Intel shares are trading lower after the company issued Q2 guidance below estimates.</a>
&nbsp;
TMUS: -6% &#x7C; <a href="https://www.benzinga.com//node/44995935">T-Mobile Shares Drop Despite Better-Than-Expected Q1 Report</a>

Movers

INTC

TMUS

Market-Moving News for April 25th

Financing

Press Releases

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Health Care

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Announces Reverse Stock Split

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

FBIO

MBIO

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Genprex

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Synaptogenix

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Xenetic Biosciences

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Mustang Bio

空売り

Mustang Bio (NASDAQ:MBIO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル